XmAb 14045

Drug Profile

XmAb 14045

Alternative Names: XmAb®14045

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Xencor
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen modulators; Immunostimulants; Interleukin 3 receptor alpha subunit modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies

Most Recent Events

  • 12 Sep 2016 Phase-I clinical trials in Haematological malignancies in USA (IV)
  • 28 Jun 2016 Xencor and Novartis agree to co-promote and co-develop XmAb® 14045 for Acute myeloid leukaemia
  • 31 Mar 2016 Xencor plans a phase I trial for Haematological malignancies in USA (NCT02730312)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top